Where I see patients (1)
My work
Cutting-edge breast cancer care
Learn about the latest findings on breast cancer risk, screening and treatment from Dr. Esserman.
Should low-risk tumors still be called cancer?
Dr. Esserman explains how using a different term could reduce unnecessary worry over cancers that are unlikely to be life-threatening.
My reviews
Selected research
-
Intratumoral Injection of mRNA-2752 and Pembrolizumab for High-Risk Ductal Carcinoma In Situ: A Phase 1 Nonrandomized Clinical Trial.
JAMA oncology
-
National yearly cost of breast cancer screening in the USA and projected cost of advocated guidelines: a simulation study with life table modelling.
BMJ open
-
A pooled analysis evaluating prognostic significance of Residual Cancer Burden in invasive lobular breast cancer.
NPJ breast cancer
Contact me
- Request appointment
- Refer a patient
- (415) 353-7070
4.8